GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Co Diagnostics Inc.
Shares of Co-Diagnostics, a molecular testing maker, soared during the pandemic on the success of its COVID-19 tests. The current chart is a story of the company searching for new sources of growth after a decline in demand and attempting to apply its technology to diagnosing other diseases.
Share prices of companies in the market segment - Medanalysis
Co-Diagnostics is a molecular diagnostics company that has developed and sells PCR tests for detecting various infectious diseases. We've categorized it as a "Medanalysis" company. The chart below shows how investors view the diagnostics sector post-pandemic.
Broad Market Index - GURU.Markets
Co-Diagnostics is a company that develops and produces innovative and affordable molecular diagnostic tests for disease detection. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Co-Diagnostics' performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
CODX - Daily change in the company's share price Co Diagnostics Inc.
The daily price change of Co-Diagnostics, Inc. reflects volatility in the molecular diagnostics sector. The indicator demonstrates high sensitivity to demand for its PCR tests, especially during infectious disease outbreaks.
Daily change in the price of a set of shares in a market segment - Medanalysis
Co-Diagnostics, Inc. is a medical diagnostics company. This chart highlights the sector's high volatility. Comparing it to CODX, whose business has grown significantly during the pandemic, helps assess its ability to adapt to new conditions.
Daily change in the price of a broad market stock, index - GURU.Markets
Co-Diagnostics is a molecular diagnostics company renowned for its COVID-19 tests. Demand for its products can spike during epidemics, creating a unique, event-driven dynamic for its stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Co Diagnostics Inc.
Co-Diagnostics, Inc.'s year-over-year performance is a story of adaptation to the post-pandemic world. Following the tremendous success of its COVID-19 tests, its 12-month market cap reflects its success in developing and commercializing new molecular tests for other infectious diseases, which is key to its long-term growth.
Annual dynamics of market capitalization of the market segment - Medanalysis
Co-Diagnostics, Inc. is a molecular diagnostics company. Following explosive growth in COVID-19 testing, it is now tasked with proving the sustainability of its core business. This chart will show how the market views its technology platform and its ability to compete in a post-pandemic world.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Co-Diagnostics, the company that skyrocketed on COVID-19 testing, is now facing a reality check. Its year-over-year performance relative to the market is the answer to the question: will it be able to diversify its business and find new revenue streams? Outperforming the market would mean it has succeeded, while lagging would mean it remains a one-hit wonder.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Co Diagnostics Inc.
Co-Diagnostics is a molecular diagnostics company. Following the pandemic boom, its monthly performance reflects its ability to diversify its business and commercialize new tests. News of approvals for non-COVID tests is the main driver.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Co-Diagnostics is a company specializing in molecular diagnostics. They developed a rapid and affordable PCR testing technology that gained widespread popularity during the pandemic. The chart below shows the overall dynamics of the medical testing sector, reflecting the boom and subsequent normalization of the diagnostic testing market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Diagnostics stocks can be volatile, especially if their revenue is dependent on a single product or event, such as a pandemic. The chart below shows overall market sentiment. Is Co-Diagnostics moving with the broader market, or is its performance driven by demand for tests?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Co Diagnostics Inc.
Co-Diagnostics, a manufacturer of molecular diagnostic tests using its proprietary CoPrimer technology, is extremely sensitive to disease news. Weekly stock prices can soar on pandemic news, as demonstrated by the demand for its COVID-19 tests.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Co-Diagnostics, like other companies in the medical diagnostics sector, is dependent on overall healthcare trends. Demand for tests and news of disease outbreaks are common factors for all. The chart shows how CODX, with its unique technology, performs compared to the industry average.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Co-Diagnostics, Inc., as a healthcare company, can exhibit defensive qualities, moving out of sync with the broader market. Pandemic news can cause its shares to surge while the rest of the market declines. The chart will help assess whether CODX exhibits these countercyclical qualities.
Market capitalization of the company, segment and market as a whole
CODX - Market capitalization of the company Co Diagnostics Inc.
The Co-Diagnostics chart is a story of pandemic-related booms and busts. This PCR test company's market cap soared during COVID-19. Its current low valuation reflects the sharp decline in demand for tests and investors' assessment of its ability to find new markets for its diagnostic technology.
CODX - Share of the company's market capitalization Co Diagnostics Inc. within the market segment - Medanalysis
Co-Diagnostics has developed a patented technology for rapid and affordable PCR tests. Its market share in medical analytics reflects the success of its platform, particularly during the COVID-19 pandemic. The chart below shows how in-demand its technology is for diagnosing various infectious diseases.
Market capitalization of the market segment - Medanalysis
Co-Diagnostics has developed a fast and affordable PCR testing technology. The chart below shows the market capitalization of the medical testing sector. The company gained notoriety during the pandemic, and its success now depends on applying its technology to other diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Co-Diagnostics is a molecular diagnostics company that has developed a rapid and affordable PCR testing technology. Its market capitalization reflects the demand for its tests. The chart below shows the economic weight of diagnostic test manufacturers.
Book value capitalization of the company, segment and market as a whole
CODX - Book value capitalization of the company Co Diagnostics Inc.
Co-Diagnostics's material foundation is its manufacturing and technology. The company's book value reflects its production capacity for PCR tests and, more importantly, its patents for the CoPrimer™ technology, which makes the tests more accurate. The chart below shows how the company transformed its base during and after the pandemic.
CODX - Share of the company's book capitalization Co Diagnostics Inc. within the market segment - Medanalysis
Co-Diagnostics, Inc. manufactures diagnostic tests at its own facilities. These production lines are its main tangible asset. The S_BCap_Seg graph shows its share of the medical testing infrastructure.
Market segment balance sheet capitalization - Medanalysis
Co-Diagnostics produces molecular diagnostic tests, including for COVID-19. This business requires certified laboratories and production lines for reagents. The book value chart shows how investments in these knowledge-intensive assets shape its business.
Book value of all companies included in the broad market index - GURU.Markets
Co-Diagnostics' assets include the production of molecular tests. The company's book value reflects its R&D laboratories and production facilities for PCR tests, including those for COVID-19. This material base is based on the patented CoPrimers™ technology, which enables the creation of more accurate and rapid tests.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Co Diagnostics Inc.
Co-Diagnostics is a molecular diagnostics company renowned for its COVID-19 tests. Its balance sheet reflects its production capacity. Its market capitalization is a volatile estimate of demand for its tests and the potential of its CoPrimer technology for diagnosing other diseases.
Market to book capitalization ratio in a market segment - Medanalysis
Co-Diagnostics is a molecular diagnostic testing company that gained prominence during the pandemic. The chart shows how the market views its patented technology and its ability to compete in the diagnostics market post-pandemic.
Market to book capitalization ratio for the market as a whole
Co-Diagnostics is a company that develops and markets molecular diagnostic tests. Its value lies in its patented technology, which enables the creation of rapid and affordable tests. The chart shows how the market has valued this technology, particularly during the pandemic, and how it is valued now.
Debts of the company, segment and market as a whole
CODX - Company debts Co Diagnostics Inc.
Co-Diagnostics, a molecular diagnostics manufacturer, uses debt to finance production and development. This chart may reflect investments in scaling up production of its PCR tests, especially during periods of high demand, and in developing new diagnostic products for various diseases.
Market segment debts - Medanalysis
Co-Diagnostics is a company that produces diagnostic tests, including for COVID-19. Demand for its products surged during the pandemic, dramatically changing its financial position. This chart shows how its balance sheet has changed and how it manages its profits.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Co Diagnostics Inc.
Co-Diagnostics develops and manufactures molecular diagnostic tests. This chart shows the company's financial policy. Following the sharp increase in demand during the pandemic, capital management, including debt, has become key. This metric reflects how the company invests its earnings in new developments or returns them to shareholders.
Market segment debt to market segment book capitalization - Medanalysis
Co-Diagnostics develops and manufactures diagnostic tests, including for COVID-19. This chart for the medical testing sector shows how companies are funding their R&D and production capacity. It helps assess the sustainability of the company's business model after the decline in pandemic demand.
Debt to book value of all companies in the market
Co-Diagnostics is a molecular diagnostics company that has developed rapid and affordable PCR tests. Demand for their products depends on the epidemiological situation and healthcare costs. The debt-to-book ratio chart reflects the overall state of the economy, which impacts healthcare budgets worldwide.
P/E of the company, segment and market as a whole
P/E - Co Diagnostics Inc.
Co-Diagnostics is a molecular diagnostics company known for its rapid and affordable PCR tests, including for COVID-19. This chart reflects its ability to adapt to the post-pandemic market. The dynamics of this indicator show how investors assess the demand for its tests for other diseases and the potential of its technology platform.
P/E of the market segment - Medanalysis
Co-Diagnostics, Inc. operates in the medical diagnostics sector. This chart shows the average P/E ratio for this industry. Comparing the company's P/E to this ratio helps understand how the market values its PCR testing technology and its potential beyond COVID-19 compared to other diagnostics companies.
P/E of the market as a whole
Co-Diagnostics is a molecular diagnostics company that developed a platform for creating rapid and affordable PCR tests. It gained recognition for its COVID-19 tests. This chart reflects sentiment in the healthcare sector. The company's valuation depends on its ability to diversify beyond COVID tests and commercialize its technology for diagnosing other diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Co Diagnostics Inc.
Co-Diagnostics has developed and markets molecular diagnostic tests based on its proprietary technology. The chart shows future revenue expectations, which depend on demand for its tests (including COVID-19 tests) and its ability to expand its product portfolio to diagnose other diseases.
%20P%2FE%20Co%20Diagnostics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Co-Diagnostics-Inc.&v=1772628764682 "Chart of the company's future (projected) P/E Co Diagnostics Inc.")
Future (projected) P/E of the market segment - Medanalysis
Co-Diagnostics has developed and markets molecular diagnostic tests, including for COVID-19, using its proprietary CoPrimers technology. This chart shows how its future revenue expectations compare to the industry average, reflecting its ability to rapidly develop and bring new tests to market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772628764689 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Co-Diagnostics is a company that produces molecular diagnostic tests. It gained widespread recognition for its COVID-19 tests. Now, its key challenge is to prove that its technology can be successfully applied in other areas, regardless of overall market sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772628764693 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Co Diagnostics Inc.
Co-Diagnostics, Inc. is a molecular diagnostics company that has developed and sells PCR tests for various diseases. Its profits can fluctuate significantly depending on outbreaks, as was the case with COVID-19. This chart shows how the demand for rapid and accurate diagnostics and competition in this market impact its financial performance.
Profit of companies in the market segment - Medanalysis
Co-Diagnostics, Inc. is a molecular diagnostics company that has developed a rapid and affordable PCR testing technology. This chart reflects the profitability of the medical analytics sector. The company gained prominence during the pandemic. Its future success depends on the application of its technology to diagnose other diseases and expansion into new markets.
Overall market profit
Co-Diagnostics, Inc. is a molecular diagnostics company that developed a rapid and affordable PCR testing technology. Its rise was driven by the COVID-19 pandemic. Now, its success depends on its ability to apply its technology to diagnose other diseases. This chart shows the backdrop against which the company is attempting to diversify its business following the pandemic boom.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Co Diagnostics Inc.
Co-Diagnostics, Inc. develops and markets molecular diagnostic tests. The company gained notoriety during the pandemic for its COVID-19 tests. This chart reflects analysts' expectations for future profits, which depend on demand for its tests after the pandemic and success in developing new diagnostic products for other diseases.
%20profit%20of%20the%20company%20Co%20Diagnostics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Co-Diagnostics-Inc.&v=1772628764709 "Graph of future (projected) profit of the company Co Diagnostics Inc.")
Future (predicted) profit of companies in the market segment - Medanalysis
Co-Diagnostics, Inc. develops and markets molecular diagnostic tests, including tests for COVID-19 and other infectious diseases. This chart shows profitability forecasts for the medical analytics sector. It reflects expectations for demand for rapid and accurate diagnostics after the pandemic.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772628764710 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Co-Diagnostics produces diagnostic tests, including for COVID-19. Demand for their products may be driven by both the epidemiological situation and overall healthcare spending. The total revenue forecast shown in the graph reflects the economic ability of governments and clinics to fund testing programs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772628764711 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Co Diagnostics Inc.
Co-Diagnostics, Inc. is a molecular diagnostics company. Its revenue has grown sharply during the pandemic thanks to COVID-19 tests. The current price-to-sales ratio reflects how investors view its ability to generate sales post-pandemic through other diagnostic products.
P/S market segment - Medanalysis
Co-Diagnostics, Inc. is a molecular diagnostics company that developed a proprietary PCR testing technology. They gained recognition for their COVID-19 tests. This chart shows how the market views their core technology and its application to other diagnostics after the pandemic subsides.
P/S of the market as a whole
Co-Diagnostics is a company that produces diagnostic tests, including for COVID-19. Its revenue grew significantly during the pandemic, but now faces uncertainty. This chart shows the average revenue estimate, which helps understand how the market values the company's revenue, which is highly dependent on the epidemiological situation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Co Diagnostics Inc.
Co-Diagnostics has developed and markets highly accurate molecular diagnostic tests, including for COVID-19. This chart reflects investor expectations for future sales, which depend on demand for infectious disease testing and the company's ability to commercialize new diagnostic panels.
%20P%2FS%20Co%20Diagnostics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Co-Diagnostics-Inc.&v=1772628764746 "The graph of the company's future (projected) P/S Co Diagnostics Inc.")
Future (projected) P/S of the market segment - Medanalysis
Co-Diagnostics, Inc. develops and markets molecular diagnostic tests based on its proprietary CoPrimer technology. This chart shows how the market estimates its future test sales, especially after the surge in demand during the pandemic. It compares it to other companies in the medical testing sector, reflecting its innovative technology.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772628764787 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Co-Diagnostics is a company that develops and markets molecular diagnostic tests, including COVID-19 tests. Its technology enables rapid and accurate testing. This chart reflects revenue expectations for the entire market, and CODX exemplifies how diagnostic innovations can drive explosive growth amid a global health crisis.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772628764801 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Co Diagnostics Inc.
Co-Diagnostics, Inc. is a molecular diagnostics company that has developed a patented technology for creating PCR tests. Its revenue, shown in this chart, is generated by selling diagnostic kits, specifically tests for COVID-19 and other infectious diseases, to laboratories worldwide.
Sales of companies in the market segment - Medanalysis
Co-Diagnostics is a molecular diagnostics company that has developed its own technology platform. This chart segments its revenue, showing revenue from sales of diagnostic tests, reagents, and equipment. This allows us to assess which component of its business is core.
Overall market sales
Co-Diagnostics, Inc. develops and markets molecular diagnostic tests. As the pandemic has demonstrated, demand for its products can be extremely volatile and dependent on disease outbreaks. This overall economic activity schedule is not key for the company, but the epidemiological situation and diagnostic innovations are.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Co Diagnostics Inc.
Co-Diagnostics is a molecular diagnostics company that has developed tests, including for COVID-19. Its revenue forecast was heavily dependent on the pandemic, but now reflects demand for its tests for other infectious diseases. This chart shows how analysts assess its ability to diversify its revenue.
%20sales%20of%20the%20company%20Co%20Diagnostics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Co-Diagnostics-Inc.&v=1772628764868 "Schedule of future (projected) sales of the company Co Diagnostics Inc.")
Future (projected) sales of companies in the market segment - Medanalysis
Co-Diagnostics, Inc. specializes in the development and production of molecular diagnostic tests. This chart shows projected revenue for the entire medical analytics sector. It reflects the demand for rapid and accurate PCR tests, particularly during infectious disease outbreaks, a key market for Co-Diagnostics' proprietary technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772628764881 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Co-Diagnostics develops and markets molecular diagnostic tests, including those for COVID-19. Demand for its products can be highly volatile and dependent on the epidemiological situation. This dynamic of general economic expectations impacts healthcare system budgets, which determine the procurement of diagnostic tests between pandemics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772628764908 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Co Diagnostics Inc.
Co-Diagnostics has developed and sells highly effective molecular diagnostic tests, including for COVID-19. This chart shows how the company monetizes its technology. Its profitability is highly dependent on testing demand, which can fluctuate dramatically depending on the epidemiological situation.
Market segment marginality - Medanalysis
Co-Diagnostics, Inc. is a molecular diagnostics company that has developed a patented PCR testing technology for disease detection. This chart shows the average profit margin in the medical testing sector. It helps assess how Co-Dx's innovative and cost-effective technology impacts its competitiveness and profitability in the global market.
Market marginality as a whole
Co-Diagnostics, Inc. is a molecular diagnostics company best known for its COVID-19 testing. This total profitability chart shows how external events like the pandemic can create massive demand for some companies' products, propelling them to new heights.
Employees in the company, segment and market as a whole
Number of employees in the company Co Diagnostics Inc.
Co-Diagnostics is a company specializing in molecular diagnostics. Its team's rapid growth likely occurred during the COVID-19 pandemic, when demand for its PCR tests was enormous. The subsequent decline in this chart reflects the normalization of demand and the company's adaptation to the post-pandemic market.
Share of the company's employees Co Diagnostics Inc. within the market segment - Medanalysis
Co-Diagnostics, Inc. is a molecular diagnostics company that has developed a patented technology for rapid and accurate PCR tests. This chart illustrates its innovative contribution to medicine. It reflects the proportion of molecular biologists and engineers working to create affordable and effective diagnostic solutions for disease detection that are united by Co-Dx.
Number of employees in the market segment - Medanalysis
Co-Diagnostics, Inc. develops and markets molecular diagnostic tests based on its proprietary technology. This chart shows employment in the medical analytics sector. Growth in this field, especially since the pandemic, reflects the high demand for rapid, accurate, and affordable PCR tests for diagnosing infectious diseases.
Number of employees in the market as a whole
Co-Diagnostics, Inc. is a molecular diagnostics company that has developed rapid and affordable tests for COVID-19 and other diseases. Accurate and rapid diagnostics are key to effective healthcare. This chart shows overall employment, and companies like these demonstrate how medical innovations can quickly scale.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Co Diagnostics Inc. (CODX)
Co-Diagnostics, Inc. is a molecular diagnostics company. Its value lies in its proprietary testing technology. This chart shows how the market values this intellectual capital. Its high cost per employee is a premium for the accuracy, speed, and cost-effectiveness of its diagnostic solutions.
%20of%20the%20company%20Co%20Diagnostics%20Inc.%20(CODX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Co-Diagnostics-Inc.-CODX&v=1772628765045 "Chart of market capitalization per employee (in thousands of dollars) of the company Co Diagnostics Inc. (CODX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Co-Diagnostics is a company specializing in molecular diagnostics. Its market value per employee reflects the value of its patented CoPrimer technology and the commercial success of its tests. Comparisons with competitors help assess its technological advantage and position in the diagnostics market.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772628765048 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Co-Diagnostics has developed and markets molecular diagnostic tests, including for COVID-19. The diagnostics business requires scientific innovation and efficient manufacturing. This chart reflects how the market evaluates the company's technology platform and its ability to create new tests for various diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772628765059 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Co Diagnostics Inc. (CODX)
Co-Diagnostics is a company specializing in molecular diagnostics (PCR tests). It experienced a colossal boom during the COVID-19 pandemic. This chart likely reflects the huge surge in revenue per employee between 2020 and 2022, and now reflects how efficiently the company is using its staff in the post-COVID era.
%20Chart%20Co%20Diagnostics%20Inc.%20(CODX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Co-Diagnostics-Inc.-CODX&v=1772628765071 "Company Profit Per Employee (in thousands of dollars) Chart Co Diagnostics Inc. (CODX)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Co-Diagnostics, Inc. is a molecular diagnostics company that developed its CoPrimer™ platform for creating rapid and accurate PCR tests. This chart reflects the value of their technology. It shows how efficiently the company can produce and sell its diagnostic kits, generating high profit margins, which is especially important during infectious disease outbreaks.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772628765080 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Co-Diagnostics, Inc. (CODX) develops and manufactures molecular diagnostic tests, including high-margin COVID-19 tests. During the pandemic, this figure was astronomical. Now, the chart shows how successfully the company is using its CoPrimers technology to develop other tests and maintain profitability after the COVID-19 recession.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772628765118 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Co Diagnostics Inc. (CODX)
Co-Diagnostics, Inc., a molecular diagnostics company, demonstrates the high volatility of its business in this chart. Revenue per employee increased sharply during the pandemic thanks to COVID-19 testing. The current trend reflects the decline in demand and the company's ability to diversify its testing portfolio.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Co-Diagnostics-Inc.-CODX&v=1772628765122 "Sales chart per company employee Co Diagnostics Inc. (CODX)")
Sales per employee in the market segment - Medanalysis
Co-Diagnostics (CODX) is a molecular diagnostics company renowned for its PCR tests (including for COVID-19) based on its patented CoPrimer™ technology. This chart shows the average revenue per employee in the segment. Comparing CODX to this benchmark demonstrates how effectively they are monetizing their PCR testing technology, especially since the pandemic.
Sales per employee for the market as a whole
Co-Diagnostics (CODX) is a company specializing in molecular diagnostics (PCR tests). This metric reflects the volatility of demand for them. During the pandemic, it skyrocketed (for COVID tests). Now, the chart shows how successfully the company is replacing this "COVID" revenue with new products.
Short shares by company, segment and market as a whole
Shares shorted by company Co Diagnostics Inc. (CODX)
Co-Diagnostics is a company that produces diagnostic tests (PCR). Its shares soared during the pandemic thanks to its COVID-19 tests. This chart shows bets that their "finest hour" has passed. Bears believe that demand for COVID tests has collapsed, and their other products won't be able to compensate for this decline, returning the company to pre-pandemic obscurity.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Co-Diagnostics-Inc.-CODX&v=1772628765134 "Short Shares Chart for the Company Co Diagnostics Inc. (CODX)")
Shares shorted by market segment - Medanalysis
Co-Diagnostics (CODX) is a one-hit wonder. The company soared on the strength of its COVID tests. This chart highlights the pessimism in the sector. The surge in short positions across the industry is a bet that the party is over. Investors don't believe CODX will be able to find a new source of revenue after the collapse in demand for COVID tests, and expect the company to burn through all its profits.
Shares shorted by the overall market
Co-Diagnostics became famous for its COVID-19 tests. This chart illustrates the overall market pessimism. Investors are wary of "single-product companies." Fear of a recession is coupled with the understanding that the COVID testing gold rush has passed. The market doesn't believe the company will be able to quickly replace lost revenue.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Co Diagnostics Inc. (CODX)
This chart shows the post-pandemic dynamics of Co-Diagnostics. The company soared on its COVID-19 PCR tests, causing a wild "overheating" (above 70). Now the market is trying to figure out whether the company can use its CoPrimer technology for other tests (such as sepsis). The sharp drop in demand for COVID tests keeps the oscillator in an "oversold" zone (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Co-Diagnostics-Inc.-CODX&v=1772628765150 "RSI 14 indicator chart for the company's stock Co Diagnostics Inc. (CODX)")
RSI 14 Market Segment - Medanalysis
Co-Diagnostics (CODX) is "PCR" 2.0. They're a diagnostics company (medtech) that soared on COVID tests. Their signature feature is their unique PCR technology (CoPrimer). The Medanalysis (diagnostics) sector thrives on R&D (and pandemics). RSI_14_Seg shows the "temperature" of the entire industry. It helps us understand: is CODX's decline a result of their "post-COVID" situation, or is the entire sector oversold?
RSI 14 for the overall market
Co-Diagnostics (CODX), a test manufacturer, sees a pandemic cycle in this chart. During periods of euphoria, demand for tests is minimal. During periods of panic (pandemics, flu outbreaks), demand for its diagnostics skyrockets, making it a unique "hedge" against health panic, but vulnerable to a "return to normal."
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CODX (Co Diagnostics Inc.)
Co-Diagnostics (CODX) has developed a proprietary technology for rapid and affordable PCR tests. This chart shows the average 12-month forecast. It reflects analysts' expectations for the company's ability to use its technology for non-COVID tests and expand into new markets.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CODX-Co-Diagnostics-Inc.&v=1772628765178 "A chart showing analyst consensus forecasts for the expected stock price. CODX (Co Diagnostics Inc.)")
The difference between the consensus estimate and the actual stock price CODX (Co Diagnostics Inc.)
Co-Diagnostics is a diagnostics company that developed CoPrimer technology for creating rapid and accurate PCR tests (including COVID-19 tests). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in their technology in a post-COVID world.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CODX-Co-Diagnostics-Inc.&v=1772628765187 "A chart showing the difference between the consensus forecast and the actual stock price. CODX (Co Diagnostics Inc.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Co-Diagnostics is a diagnostics company renowned for its PCR tests for COVID. It is now exploring applying its technology (CoPrimers) to tests for other diseases. This chart reflects analysts' general expectations for the entire medical testing sector. It shows whether experts believe a "post-COVID" life exists for these companies.
Analysts' consensus forecast for the overall market share price
Co-Diagnostics is a company specializing in molecular diagnostics (PCR tests), which has seen a sharp rise during the pandemic thanks to its COVID-19 tests. This chart shows overall market sentiment. For CODX, which is searching for new growth drivers post-pandemic, overall optimism is important, as it reflects risk appetite and investor confidence in its new developments.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Co Diagnostics Inc.
Co-Diagnostics is a one-hit wonder of the COVID era. They developed the highly accurate Co-Primer (PCR test), which earned them millions during the pandemic. Now the party is over. This chart is a summary of their post-COVID life. It reflects their (disappearing) COVID revenue and their desperate attempts to leverage their technology for R&D in other infectious diseases.
AKIMA Market Segment Index - Medanalysis
Co-Diagnostics (CODX) is a molecular diagnostics company. They developed and commercialized their CoPrimer technology, which enables the creation of rapid and accurate PCR tests (including COVID-19 tests). The chart shows the average index for the segment, helping investors assess how competitive this diagnostic technology is compared to the average.
The AKIM Index for the overall market
Co-Diagnostics is a manufacturer of low-cost molecular diagnostic tests (PCR) and the Co-Dx platform for laboratories and point-of-care. This chart, reflecting the market average, is a backdrop. It helps assess how Co-Dx, which is adapting after the COVID boom, compares to overall macroeconomic trends in diagnostics.
